Patheon OneSource™

Article

Sponsored Content

Patheon OneSource™ helps small and emerging pharmaceutical companies lower risk and drive more predictable outcomes by integrating drug substance and drug product development decisions within a single CDMO.

Patheon is a leading global provider of outsourced pharmaceutical development and manufacturing services. We provide a comprehensive, integrated and highly customizable range of active pharmaceutical ingredient, or API, and finished drug product services to our customers. From formulation development to clinical and commercial-scale manufacturing, packaging, and life cycle management, our services support both small molecule and large molecule drugs. We believe we are the only end-to-end integrated provider of such services, which, combined with our scientific and regulatory expertise and specialized capabilities, allows our customers to work with an outsourcing partner to address their most complex development and manufacturing needs.

 

Through the company’s end-to-end integrated service offering, known as “Patheon OneSource,” clients have access to comprehensive solutions for both small and large molecule drugs across Patheon’s three main segments, including development and manufacturing services for API (Drug Substance Services, or DSS), formulation development and pre-clinical and clinical drug product manufacturing (Pharmaceutical Development Services, or PDS), and commercial drug product manufacturing and packaging (Drug Product Services, or DPS).

 

Over the last 10 years, Patheon has supported the delivery of 112 NDA-approved drugs - more than 2.5x the nearest competitor, and as many as the next six leading CMOs combined. A Healthier World. Delivered.

 

Contact Details:

Company name: Patheon
Website: http://www.patheon.com
E-mail: doingbusiness@patheon.com

Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Related Content